Analyst Price Target is $68.00
▲ +1,434.99% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Lipocine in the last 3 months. The average price target is $68.00, with a high forecast of $68.00 and a low forecast of $68.00. The average price target represents a 1,434.99% upside from the last price of $4.43.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Lipocine. This rating has held steady since August 2022, when it changed from a Buy consensus rating.
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.